Hologic (HOLX) is Downgraded by Needham to Hold

Hologic (HOLX) was Downgraded by Needham to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Needham advised their investors in a research report released on Apr 28, 2016.

On the company’s financial health, Hologic reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.46. The company had revenue of $693.30 million for the quarter, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Hologic opened for trading at $37.46 and hit $38.05 on the upside on Wednesday, eventually ending the session at $37.83, with a gain of 0.34% or 0.13 points. The heightened volatility saw the trading volume jump to 35,16,102 shares. Company has a market cap of $10,737 M.

In a different news, on Feb 26, 2016, David R Jr Lavance (director) sold 11,621 shares at $34.50 per share price. According to the SEC, on Nov 12, 2015, Lawrence M Levy (director) sold 20,000 shares at $40.35 per share price. On Sep 9, 2015, Wayne Wilson (director) sold 100,000 shares at $39.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.


Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.